LLY Eli Lilly and Company Loading... : Bullish and Bearish Analyst Opinions
From LLY earnings callsLoading chart...
Top Calls
Feed
14:00
Aug 05
Aug 05
Management raised full-year guidance for revenue, margin, and EPS, reflecting very strong first-half momentum and confidence in continued growth across the incretin portfolio and other therapeutic areas.
HIGH
14:00
Apr 30
Apr 30
Guidance raised on the strength of Zepbound and Mounjaro volumes globally, with revenue growth of 28% expected for the full year. The tone is confident about the momentum in the incetin market and the launch of orforglipron.
HIGH
15:00
Feb 04
Feb 04
Management's tone is bullish, with strong top-line growth guidance driven by the launch of orforglipron, Medicare expansion, and continued strength in its incretin portfolio, despite anticipated price headwinds.
HIGH
About LLY Analyst Coverage
Buzzberg tracks LLY (Eli Lilly and Company) across 1 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 3 total trade ideas tracked. Latest voices: Lucas Montarce, Lucas Montarse.